Eli Lilly And Co
NYSE: LLY
Stock price
1257.03 USD
(+428.43%) 5 years
Financial Performance
5Y price score: 600
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 1,529.9%
%
ㅤ
By default your notes are visible only to you.
793.8
52-week range
1292.6
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
1.8 %
Dividend Yield TTM
0.5 %
Market cap $
$ 1,183,314
Price / Earnings TTM
42.2
Price / Book TTM
33.1
PEG TTM
0.4
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
54.1 %
438.1 %
1,529.8 %
Free cash flow per share growth
508.7 %
113.8 %
725.1 %
Earnings per share growth
26.2 %
254.7 %
952.8 %
Founded: 1,876
Employees: 43,000
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q2 (Aug 5, 2026)
1) Strong Financial Performance - Revenue growth of 48% YoY, driven by Key Products, particularly Oncology, Immunology, and Neuroscience, which collectively grew 121%. - Non-GAAP earnings per share reached $8.38, up from $6.31 in Q2 2025. - Gross margin improved to 86.3%, reflecting a favorable product mix and production costs. - U.S. revenue increased by 33%, with notable contributions from Zepbound and Mounjaro.
2) Pipeline Advancements and Regulatory Milestones - Significant progress in the pipeline, including FDA approval of Ebglyss for atopic dermatitis and EU approval for Jaypirca in CLL. - Foundayo launched in the U.S. for obesity, with early uptake in the UAE showing promise. Regulatory reviews ongoing in over 40 countries. - Positive Phase 3 results for retatrutide in obesity and diabetes, with plans for a BLA submission in Q1 2027.
3) Strategic Acquisitions and Business Development - Acquired companies like Curevo and AtaiBeckley to expand into infectious diseases and mental health treatments. - Focus on building a robust internal pipeline through strategic business development, enhancing Lilly's position in emerging therapeutic areas.
4) Market Dynamics and Competitive Landscape - The Medicare GLP-1 Bridge program launched, increasing access to obesity medicines for 20 million Americans. - Foundayo's U.S. launch is gaining momentum, with a noted increase in prescribers from 8,000 to 36,000. - Competitive pressures from other oral treatments in the obesity market, particularly in the UAE, but Lilly maintains a strong market position.
5) Guidance and Future Outlook - Full-year revenue guidance raised to between $85 billion and $87 billion, reflecting strong performance. - Non-GAAP performance margin expected between 49% and 50.5%. - Anticipated deceleration in revenue growth in the latter half of 2026 due to prior period adjustments and seasonality effects.
Bottom line: Eli Lilly's robust financial performance, strategic pipeline advancements, and proactive market positioning suggest a strong outlook for continued growth, making it an attractive prospect for shareholders despite potential competitive challenges.
Annual Reports, Presentations And IR Contacts
Go to the websiteEli Lilly And Co — Financial Overview, Stock Price, Market Cap
Eli Lilly And Co is a company. Founded in 1876. As of October 19, 2026, the company's market capitalization is $1183314086501 with a current stock price of $1257.03.